The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new ... are building in its earlier ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell ... “Looking forward to building on Kite’s legacy ...